On Mar. 20, 2020, Amneal Pharma announced that it was responding to the national COVID-19 health emergency by building on its existing supply of hydroxychloroquine sulfate.

Amneal was ramping up production of hydroxychloroquine sulfate at several of its manufacturing sites and expected to produce approximately 20 million tablets between now and mid-April. Those tablets were made available nationwide through Amneal’s existing retail and wholesale customers, as well as through direct sales to larger institutions in need.